Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries-Reference-Cited by-同舟云学术

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Published:2021-02 Issue: Volume:319 Page:108-117
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Futema Marta,Ramaswami Uma^ORCID,Tichy Lukas,Bogsrud Martin P.,Holven Kirsten B.,Roeters van Lennep Jeanine,Wiegman Albert,Descamps Olivier S.^ORCID,De Leener Anne,Fastre Elodie,Vrablik Michal^ORCID,Freiberger Tomas^ORCID,Esterbauer Harald,Dieplinger Hans^ORCID,Greber-Platzer Susanne,Medeiros Ana M.,Bourbon Mafalda,Mollaki Vasiliki^ORCID,Drogari Euridiki^ORCID,Humphries Steve E.

Funder

Pfizer

Fondation Leducq

Fundação para a Ciência e a Tecnologia

British Heart Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference43 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur. Heart J.,2013

2. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis;Akioyamen;BMJ Open,2017